Studies with pharmacologic inhibitors reveal YAP/TEAD dependency in cancers with HIPPO pathway mutations (such as mesotheliomas with NF2 loss) but not more broadly, even in tumors with robust YAP/TEAD activation (26, 41). This evidence concerns the gene YAP1 and cancer.